HIV-1 gp41 Fusion Intermediate: A Target for HIV Therapeutics

Journal of the Formosan Medical Association

Volumn 109, Issue 2, 2010, Pages 94-105

  Pan, Chungen ^a,b   Liu, Shuwen ^c   Jiang, Shibo ^a,c  

^a NEW YORK BLOOD CENTER   (United States)

^b PEKING UNIVERSITY   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

fusion inhibitor; gp41; HIV 1; peptide; therapeutics

Indexed keywords

ADS J1; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; C52L; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CP32; ENFUVIRTIDE; GLYCOPROTEIN GP 41; HR212; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; NCCG GP41; RECOMBINANT PROTEIN; SC34EK; SIFUVIRTIDE; TIFUVIRTIDE; UNCLASSIFIED DRUG; VIRUS INHIBITORY PEPTIDE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE; CONFORMATIONAL TRANSITION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REVIEW; TARGET CELL; VIRUS ATTACHMENT; VIRUS ENVELOPE; VIRUS STRAIN;

ANTI-HIV AGENTS; DRUG DESIGN; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; RECEPTORS, CCR5; RECEPTORS, CXCR4;

EID: 77449151492     PISSN: None     EISSN: 09296646     Source Type: Journal    
DOI: 10.1016/S0929-6646(10)60029-0     Document Type: Review

References (89)

1. Huang L.M., and Jeang K.T. HIV-1 at age 25: some thoughts for Taiwan and China. J Formos Med Assoc 107 (2008) 907-908
2. Barre-Sinoussi F., Chermann J.C., Rey F., et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220 (1983) 868-871
3. Gallo R.C., Salahuddin S.Z., Popovic M., et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224 (1984) 500-503
4. FDA-approved antiretrovial (ARV) drugs. Available at http://www.hivandhepatitis.com/hiv_and_aids/hiv_treat.html [Date accessed: September 14, 2009]
5. De Clercq E. Antiviral drugs in current clinical use. J Clin Virol 30 (2004) 115-133
6. Johnson V.A., Brun-Vézinet F., Clotet B., et al. Drug resistance mutations in HIV-1. Top HIV Med 11 (2003) 215-221
7. Richman D.D., Morton S.C., Wrin T., et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 18 (2004) 1393-1401
8. Carr A., and Cooper D.A. Adverse effects of antiretroviral therapy. Lancet 356 (2000) 1423-1430
9. Chan D.C., Chutkowski C.T., and Kim P.S. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci USA 95 (1998) 15613-15617
10. Jiang S., Zhao Q., and Debnath A.K. Peptide and non-peptide HIV fusion inhibitors. Curr Pharm Des 8 (2002) 563-580
11. Liu S., Lu H., Niu J., et al. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Biol Chem 280 (2005) 11259-11273
12. Liu S., Jing W., Cheung B., et al. HIV gp41 C-terminal hep-tad repeat contains multifunctional domains: relation to mechanisms of action of anti-HIV peptides. J Biol Chem 282 (2007) 9612-9620
13. Qi Z., Shi W., Xue N., et al. Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors. J Biol Chem 283 (2008) 30376-30384
14. Lu M., Blacklow S.C., and Kim P.S. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 2 (1995) 1075-1082
15. Ji H., Shu W., Burling F.T., et al. Inhibition of HIV-1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion. J Virol 73 (1999) 8578-8586
16. Dwyer J.J., Hasan A., Wilson K.L., et al. The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation. Biochemistry 42 (2003) 4945-4953
17. Chan D.C., Fass D., Berger J.M., et al. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89 (1997) 263-273
18. Weissenhorn W., Dessen A., Harrison S.C., et al. Atomic Structure of the Ectodomain from HIV-1 gp41. Nature 387 (1997) 426-428
19. Chan D.C., and Kim P.S. HIV entry and its inhibition. Cell 93 (1998) 681-684
20. Jiang S., Siddiqui P., and Liu S. Blocking viral entry: a complementary strategy for HIV therapy. Drug Discovery Today: Therapeutic Strategies 1 (2004) 497-503
21. Liu S., Wu S., and Jiang S. HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds. Curr Pharm Design 13 (2007) 143-162
22. Jiang S., Lin K., Strick N., et al. HIV-1 inhibition by a peptide. Nature 365 (1993) 113
23. Jiang S., Lin K., Strick N., et al. Inhibition of HIV-1 infection by a fusion domain binding peptide from HIV-1 envelope glycoprotein gp41. Biochem Biophys Res Commun 195 (1993) 533-538
24. Wild C.T., Shugars D.C., Greenwell T.K., et al. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 91 (1994) 9770-9774
25. Lu M., and Kim P.S. A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J Biomol Struct Dyn 15 (1997) 465-471
26. Lu M., Ji H., and Shen S. Subdomain folding and biological activity of the core structure from human immunodeficiency virus type 1 gp41: implications for viral membrane fusion. J Virol 73 (1999) 4433-4438
27. Tan K., Liu J., Wang J., et al. Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci USA 94 (1997) 12303-12308
28. Kliger Y., Gallo S.A., Peisajovich S.G., et al. Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage. J Biol Chem 276 (2001) 1391-1397
29. Peisajovich S.G., Gallo S.A., Blumenthal R., et al. C-terminal octylation rescues an inactive T20 mutant: implications for the mechanism of HIV/SIV-induced membrane fusion. J Biol Chem 278 (2003) 21012-21017
30. Kilby J.M., and Eron J.J. Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med 348 (2003) 2228-2238
31. Wei X., Decker J.M., Liu H., et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46 (2002) 1896-1905
32. Xu L., Hué S., Taylor S., et al. Minimal variation in T-20 binding domain of different HIV-1 subtypes from antiretroviralnaive and -experienced patients. AIDS 16 (2002) 1684-1686
33. Lu J., Deeks S.G., HOh R., et al. Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J Acquir Immune Defic Syndr 43 (2006) 6-14
34. Sista P.R., Melby T., Davison D., et al. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS 18 (2004) 1787-1794
35. Kilby J.M., Lalezari J.P., Eron J.J., et al. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses 18 (2002) 685-693
36. Chinnadurai R., Rajan D., Munch J., et al. Human immunodeficiency virus type 1 variants resistant to first- and secondversion fusion inhibitors and cytopathic in ex vivo human lymphoid tissue. J Virol 81 (2007) 6563-6572
37. Eron J.J., Gulick R.M., Bartiett J.A., et al. Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. J Infect Dis 189 (2004) 1075-1083
38. Menzo S., Castagna A., Monachetti A., et al. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. Antimicrob Agents Chemother 48 (2004) 3253-3259
39. Lalezari J.P., Bellos N.C., Sathasivam K., et al. T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen. J Infect Dis 191 (2005) 1155-1163
40. Melby T., Demasi R., Cammack N., et al. Evolution of Genotypic and Phenotypic Resistance during Chronic Treatment with the Fusion Inhibitor T-1249. AIDS Res Hum retroviruses 23 (2007) 1366-1373
41. Delmedico M, Bray B, Cammack N, et al. Next generation HIV peptide fusion inhibitor candidates achieve potent, durable suppression of virus replication in vitro and improved pharmacokinetic properties. In: 13th Conference on Retroviruses and Opportunistic Infections, 2006;5-8 [Abstract].
42. Dwyer J.J., Wilson K.L., Davison D.K., et al. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc Natl Acad Sci USA 104 (2007) 12772-12777
43. He Y., Xiao Y., Song H., et al. Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem 283 (2008) 11126-11134
44. FusoGen. Available at: http://www.fusogen.com [Date accessed: September 14, 2009]
45. Wild C., Oas T., McDanal C., et al. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci USA 89 (1992) 10537-10541
46. He Y., Cheng J., Li J., et al. Identification of a critical motif for the HIV-1 gp41 core structure: implication for designing novel anti-HIV fusion inhibitors. J Virol 82 (2008) 6349-6358
47. He Y., Cheng J., Lu H., et al. Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains. Proc Natl Acad Sci USA 105 (2008) 16332-16337
48. Otaka A., Nakamura M., Nameki D., et al. Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells. Angew Chem Int Ed Engl 41 (2002) 2937-2940
49. Sia S.K., Carr P.A., Cochran A.G., et al. Short constrained pep-tides that inhibit HIV-1 entry. Proc Natl Acad Sci USA 99 (2002) 14664-14669
50. Eckert D.M., Malashkevich V.N., and Kim P.S. Crystal structure of GCN4-pIQI, a trimeric coiled coil with buried polar residues. J Mol Biol 284 (1998) 859-865
51. Eckert D.M., Malashkevich V.N., Hong L.H., et al. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 99 (1999) 103-115
52. Welch B.D., VanDemark A.P., Heroux A., et al. Potent D-pep-tide inhibitors of HIV-1 entry. Proc Natl Acad Sci USA 104 (2007) 16828-16833
53. Deng Y., Zheng Q., Ketas T.J., et al. Protein design of a bacte-rially expressed HIV-1 gp41 fusion inhibitor. Biochemistry 46 (2007) 4360-4369
54. Veazey R.S., Klasse P.J., Schader S.M., et al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 438 (2005) 99-102
55. Ni L., Gao G.F., and Tien P. Rational design of highly potent HIV-1 fusion inhibitory proteins: implication for developing antiviral therapeutics. Biochem Biophys Res Commun 332 (2005) 831-836
56. Pang W., Wang R.R., Yang L.M., et al. Recombinant protein of heptad-repeat HR212, a stable fusion inhibitor with potent anti-HIV action in vitro. Virology 377 (2008) 80-87
57. Louis J.M., Nesheiwat I., Chang L., et al. Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion. J Biol Chem 278 (2003) 20278-20285
58. Root M.J., Kay M.S., and Kim P.S. Protein design of an HIV-1 entry inhibitor. Science 291 (2001) 884-888
59. Root M.J., and Hamer D.H. Targeting therapeutics to an exposed and conserved binding element of the HIV-1 fusion protein. Proc Natl Acad Sci USA 100 (2003) 5016-5021
60. Munch J., Ständker L., Adermann K., et al. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell 129 (2007) 263-275
61. Jiang S., Lin K., and Lu M. A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the HIV-1 envelope glycoprotein. J Virol 72 (1998) 10213-10217
62. Jiang S., Lin K., Zhang L., et al. A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody. J Virol Methods 80 (1999) 85-96
63. Debnath A.K., Radigan L., and Jiang S. Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodecifiency virus type 1. J Med Chem 42 (1999) 3203-3209
64. Jiang S., and Debnath A.K. A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity. Biochem Biophys Res Commun 270 (2000) 153-157
65. He Y., Liu S., Jing W., et al. Conserved residue Lys574 in the cavity of HIV-1 gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry. J Biol Chem 282 (2007) 25631-25639
66. He Y., Liu S., Li J., et al. Conserved salt-bridge between the N- and C-terminal heptad repeat regions of HIV-1 gp41 core structure is critical for virus entry and inhibition. J Virol 82 (2008) 11129-11139
67. Jiang S., Lu H., Liu S., et al. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob Agents Chemother 48 (2004) 4349-4359
68. Liu K., Lu H., Hou L., et al. Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41. J Med Chem 51 (2008) 7843-7854
69. Katritzky A.R., Tala S.R., Lu H., et al. Design, synthesis, and structure-activity relationship of a novel series of 2-Aryl 5-(4-oxo-3-phenethyl-2-thioxothiazolidin-ylidenemethyl)furans as HIV-1 entry inhibitors. J Med Chem 52 (2009) 7631-7639
70. Ferrer M., Kapoor T.M., Strassmaier T., et al. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements. Nat Struct Biol 6 (1999) 953-960
71. Ernst J.T., Kutzki O., Debnath A.K., et al. Design of a protein surface antagonist based on alpha-helix mimicry: inhibition of gp41 assembly and viral fusion. Angew Chem Int Ed Engl 41 (2002) 278-281
72. Xu Y., Lu H., Kennedy J.P., et al. Evaluation of "credit card" libraries for inhibition of HIV-1 gp41 fusogenic core formation. J Comb Chem 8 (2006) 531-539
73. Gochin M., Savage R., Hinckley S., et al. A fluorescence assay for rapid detection of ligand binding affinity to HIV-1 gp41. Biol Chem 387 (2006) 477-483
74. Cai L., and Gochin M. A novel fluorescence intensity screening assay identifies new low molecular weight inhibitors of the gp41 coiled coil domain of HIV-1. Antimicrob Agents Chemother 51 (2007) 2388-2395
75. Ho D.D. Therapy of HIV infections: problems and prospects. Bull N Y Acad Med 73 (1996) 37-45
76. Nagashima K.A., Thompson D.A., Rosenfield, et al. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J Infect Dis 183 (2001) 1121-1125
77. Tremblay C.L., Kollmann C., Giguel F., et al. Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. J Acquir Immune Defic Syndr 25 (2000) 99-102
78. Tremblay C.L., Giguel F., Kollmann C., et al. Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrob Agents Chemother 46 (2002) 1336-1339
79. Pan C., Lu H., Qi Z., et al. Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors. AIDS 23 (2009) 639-641
80. Pan C., Cai L., Lu H., et al. Combinations of the first and next generation HIV fusion inhibitors exhibit highly potent synergistic effect against enfuvirtide-sensitive and resistant HIV-1 strains. J Virol 83 (2009) 7862-7872
81. Rimsky L.T., Shugars D.C., and Matthews T.J. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol 72 (1998) 986-993
82. Eggink D., Baldwin C.E., Deng Y., et al. Selection of T1249-resistant Human Immunodeficiency Virus type 1 variants. J Virol 82 (2008) 6678-6688
83. Greenberg M.L., and Cammack N. Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 54 (2004) 333-340
84. Labrosse B., Morand-Joubert L., Goubard A., et al. Role of the envelope genetic context in the development of enfu-virtide resistance in human immunodeficiency virus type 1-infected patients. J Virol 80 (2006) 8807-8819
85. Matthews T., Salgo M., Greenberg M., et al. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov 3 (2004) 215-225
86. Mink M., Mosier S.M., Janumpalli S., et al. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J Virol 79 (2005) 12447-12454
87. Ray N., Harrison J.E., Blackbum L.A., et al. Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors. J Virol 81 (2007) 3240-3250
88. Ray N., Blackburn L.A., and Doms R.W. HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide. J Virol 83 (2009) 2989-2995
89. Trivedi V.D., Cheng S.F., Wu C.W., et al. The LLSGIV stretch of the N-terminal region of HIV-1 gp41 is critical for binding to a model peptide, T20. Protein Eng 16 (2003) 311-317